Ki67
Methodology
Immunohistochemistry (IHC)
Test Description and clinical significance
Disease:
Breast Cancer
Lymphomas (NHL)
Marker of cell proliferation. Labile, nonhistone nuclear protein expressed in G1, S, G2 and M phases of cell cycle, then rapidly catabolized at end of M phase and not detectable in G0 and early G1 cells. The expression of the Ki-67 protein is used to assess tumor cell proliferation in breast cancer.
The Ki-67 labeling index which is the fraction of Ki-67-positive tumor cells is often correlated with the clinical course of the disease.
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed for extended periods
Storage & Transport
Room Temperature
CPT(s)
88360
New York Approved
YES
TAT
1 Day
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
